MedTrace Logo

RW Effectiveness of Lurbinectedin in Extensive Stage SCLC

NCT05285033 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 312

Last updated 2023-01-06

No results posted yet for this study

Summary

LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness and safety of lurbinectedin in real-world conditions.

Conditions

  • Small-cell Lung Cancer

Interventions

DRUG

Lurbinectedin

Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).

Sponsors & Collaborators

  • Groupe Francais De Pneumo-Cancerologie

    collaborator OTHER

  • PharmaMar

    collaborator INDUSTRY

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Nicolas Girard · Institut Curie

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05285033 on ClinicalTrials.gov